Log in
LON:MTFB

Motif Bio plc (MTFB.L) News Headlines

GBX 0.50
0.00 (0.00 %)
(As of 07/29/2020)
Add
Compare
Today's Range
0.50
Now: GBX 0.50
0.50
50-Day Range
0.50
MA: GBX 0.50
0.50
52-Week Range
0.03
Now: GBX 0.50
3.20
VolumeN/A
Average Volume33.38 million shs
Market Capitalization£3.27 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Motif Bio plc (MTFB.L) (LON MTFB) News Headlines Today

Source:
SourceHeadline
Cash Shell Motif Bio Swings To Interim Loss On Derivative LiabilitiesCash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities
lse.co.uk - October 12 at 7:54 AM
Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment PhaseMotif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase
www.bloomberg.com - June 10 at 7:32 PM
Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working GroupMotif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group
www.bloomberg.com - May 23 at 12:03 AM
Motif Bio Share ChatMotif Bio Share Chat
www.lse.co.uk - December 27 at 12:55 AM
Motif Bio to file for voluntary delistingMotif Bio to file for voluntary delisting
seekingalpha.com - November 26 at 8:16 AM
Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital MarketMotif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market
finance.yahoo.com - November 26 at 3:15 AM
Motif Bio Meeting With US FDA Confirms Need For Another iclaprim TrialMotif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial
www.lse.co.uk - October 10 at 7:31 AM
Motif Bio submits Type B meeting request to FDAMotif Bio submits Type B meeting request to FDA
seekingalpha.com - July 15 at 10:14 AM
HOME, CLDR and MIK among premarket losersHOME, CLDR and MIK among premarket losers
seekingalpha.com - June 6 at 10:23 AM
Motif Bio not quite there with iclaprim NDA; shares down 35% premarketMotif Bio not quite there with iclaprim NDA; shares down 35% premarket
seekingalpha.com - June 6 at 10:23 AM
Motif Bio to evaluate iclaprim in ophthalmology; shares up 8% premarketMotif Bio to evaluate iclaprim in ophthalmology; shares up 8% premarket
seekingalpha.com - May 22 at 10:04 AM
Motif Bio meeting with U.S. FDA held as plannedMotif Bio meeting with U.S. FDA held as planned
finance.yahoo.com - May 3 at 5:41 PM
Motif Bio +10% on new Iclaprim dataMotif Bio +10% on new Iclaprim data
seekingalpha.com - April 16 at 11:20 AM
Motif Bio Reports Fiscal Year 2018 ResultsMotif Bio Reports Fiscal Year 2018 Results
finance.yahoo.com - April 15 at 10:20 AM
Motif Bio granted meeting with regarding iclaprim; shares up 57% premarketMotif Bio granted meeting with regarding iclaprim; shares up 57% premarket
seekingalpha.com - March 21 at 8:51 AM
Motif Bio plc Estimate MomentumMotif Bio plc Estimate Momentum
www.nasdaq.com - March 20 at 10:52 PM
AUPH, LXRX and TEUM among premarket gainersAUPH, LXRX and TEUM among premarket gainers
seekingalpha.com - March 20 at 9:45 AM
MTFB: FDA Issues CRL for Iclaprim…MTFB: FDA Issues CRL for Iclaprim…
finance.yahoo.com - February 20 at 10:36 AM
Motif Bio down 17% premarket on expected capital raiseMotif Bio down 17% premarket on expected capital raise
seekingalpha.com - February 19 at 10:32 AM
SIX, MTFB and NTAP among premarket losersSIX, MTFB and NTAP among premarket losers
seekingalpha.com - February 14 at 10:13 AM
Motif Bio PLC ADRMotif Bio PLC ADR
www.barrons.com - January 11 at 5:03 PM
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.